Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
复制标题
DOI：
10.1136/annrheumdis-2013-203440
复制
发表时间：
2014-01-01
影响因子：
27.4
通讯作者：
Emery, P.
中科院分区：
文献类型：
--
作者：
Nam, J. L.;Villeneuve, E.;Emery, P.
目的比较甲氨蝶呤（MTX）和英夫利昔单抗（IFX）与MTX和静脉注射皮质类固醇诱导缓解对未使用过疾病缓解抗风湿药物（DMARD）的早期类风湿关节炎（RA）的疗效。112例初治RA患者（1987年美国风湿病学会分类标准），疾病活动性评分44（DAS 44）>2.4，随机分为MTX + IFX或MTX + IFX组。单次静脉注射甲泼尼龙250 mg。如果DAS 44>2.4，则采用达标治疗方法，并进行治疗递增。在IFX组中，IFX因持续缓解而停用（DAS 44
Objectives In disease modifying antirheumatic drug (DMARD)-naive early rheumatoid arthritis (RA), to compare the efficacy of methotrexate (MTX) and infliximab (IFX) with MTX and intravenous corticosteroid for remission induction.Methods In a 78-week multicentre randomised controlled trial, double-blinded to week 26, 112 treatment-naive RA patients (1987 American College of Rheumatology classification criteria) with disease activity score 44 (DAS44)>2.4 were randomised to MTX + IFX or MTX + single dose intravenous methylprednisolone 250mg. A treat-to-target approach was used with treatment escalation if DAS44>2.4. In the IFX group, IFX was discontinued for sustained remission (DAS44